Haemonetics Corporation
HAE
$57.17
$0.280.49%
NYSE
| 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 2.76% | -3.48% | -15.87% | 1.87% | 32.18% |
| Total Depreciation and Amortization | 25.30% | 18.78% | 10.82% | 4.49% | -7.15% |
| Total Amortization of Deferred Charges | 0.11% | -7.63% | -3.01% | -10.39% | 394.83% |
| Total Other Non-Cash Items | -75.37% | -68.25% | -44.34% | 10.90% | 75.60% |
| Change in Net Operating Assets | -64.17% | -883.77% | -411.10% | -392.91% | -295.62% |
| Cash from Operations | -34.48% | -67.61% | -45.94% | -33.44% | -24.56% |
| Capital Expenditure | 32.92% | 14.68% | 10.60% | 39.84% | 48.62% |
| Sale of Property, Plant, and Equipment | 542.27% | 528.12% | 1,339.81% | 12.56% | -158.18% |
| Cash Acquisitions | 38.12% | -- | -- | -8,456.21% | -8,456.21% |
| Divestitures | -- | -- | 76.47% | 76.47% | -100.00% |
| Other Investing Activities | -87.27% | 29.44% | 64.97% | 53.17% | 69.50% |
| Cash from Investing | 41.04% | -368.44% | -342.63% | -124.21% | -104.21% |
| Total Debt Issued | 763.64% | -- | 221.21% | -66.67% | -66.67% |
| Total Debt Repaid | -6,117.38% | -1,014.49% | -95.33% | 78.73% | 96.93% |
| Issuance of Common Stock | 14.20% | 19.43% | 2.40% | 2.82% | -0.06% |
| Repurchase of Common Stock | -1,348.48% | -1,352.19% | 81.50% | 92.15% | 92.15% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,740.80% | -2,516.65% | -1,055.86% | 95.95% | 97.00% |
| Cash from Financing | 96.66% | 616.17% | 580.16% | 138.02% | 193.05% |
| Foreign Exchange rate Adjustments | -27,881.82% | 101.90% | -171.57% | 19.08% | 99.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 522.56% | -147.10% | -17.04% | -523.17% | -133.20% |